Patents by Inventor Mark Marchionni

Mark Marchionni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR CARDIOMYOCYTE SURVIVAL, PROLIFERATION OR DIFFERENTIATION BY NRG-2
    Publication number: 20200354422
    Abstract: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.
    Type: Application
    Filed: June 5, 2020
    Publication date: November 12, 2020
    Inventor: Mark Marchionni
  • Methods for cardiomyocyte survival, proliferation or differentiation by NRG-2
    Patent number: 10717775
    Abstract: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: July 21, 2020
    Assignee: Acorda Therapeutics, Inc.
    Inventor: Mark Marchionni
  • METHODS FOR PROTECTING DOPAMINERGIC NEURONS FROM STRESS AND PROMOTING PROLIFERATION AND DIFFERENTIATION OF OLIGODENDROCYTE PROGENITORS BY NRG-2
    Publication number: 20190169248
    Abstract: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.
    Type: Application
    Filed: August 29, 2018
    Publication date: June 6, 2019
    Inventor: Mark Marchionni
  • Methods for treating congestive heart failure
    Patent number: 10232016
    Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: March 19, 2019
    Assignees: Acorda Therapeutics, Inc., Beth Israel Deaconess Medical Center, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Mark Marchionni, Ralph Kelly, Beverly Lorell, Douglas B. Sawyer
  • Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by NRG-2
    Patent number: 10065999
    Abstract: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 4, 2018
    Assignee: Acorda Therapeutics, Inc.
    Inventor: Mark Marchionni
  • Methods for Treating Congestive Heart Failure
    Publication number: 20160113998
    Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.
    Type: Application
    Filed: September 3, 2015
    Publication date: April 28, 2016
    Inventors: Mark Marchionni, Ralph Kelly, Beverly Lorell, Douglas B. Sawyer
  • METHODS FOR PROTECTING DOPAMINERGIC NEURONS FROM STRESS AND PROMOTING PROLIFERATION AND DIFFERENTIATION OF OLIGODENDROCYTE PROGENITORS BY NRG-2
    Publication number: 20150274795
    Abstract: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.
    Type: Application
    Filed: December 19, 2014
    Publication date: October 1, 2015
    Inventor: Mark Marchionni
  • Methods for treating congestive heart failure
    Patent number: 8394761
    Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: March 12, 2013
    Assignees: Beth Israel Deaconess Medical Center, The Brigham and Women's Hospital, Inc., Acorda Therapeutics, Inc.
    Inventors: Mark Marchionni, Ralph Kelly, Beverly Lorell, Douglas B. Sawyer
  • METHODS FOR PROTECTING DOPAMINERGIC NEURONS FROM STRESS AND PROMOTING PROLIFERATION AND DIFFERENTIATION OF OLIGODENDROCYTE PROGENITORS BY NRG-2
    Publication number: 20120214737
    Abstract: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 23, 2012
    Applicant: Acorda Therapeutics, Inc.
    Inventor: Mark Marchionni
  • METHODS FOR TREATING CONGESTIVE HEART FAILURE
    Publication number: 20120065130
    Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.
    Type: Application
    Filed: November 9, 2011
    Publication date: March 15, 2012
    Inventors: Mark Marchionni, Ralph Kelly, Beverly Lorell, Douglas B. Sawyer
  • Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by NRG-2
    Patent number: 8114838
    Abstract: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.
    Type: Grant
    Filed: March 21, 2005
    Date of Patent: February 14, 2012
    Assignee: Acorda Therapeutics, Inc.
    Inventor: Mark Marchionni
  • Methods for treating congestive heart failure
    Patent number: 8076283
    Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: December 13, 2011
    Assignees: Acorda Therapeutics, Inc., Beth Israel Deaconesss Medical Center, The Brigham and Women's Hospital, Inc.
    Inventors: Mark Marchionni, Ralph Kelly, Beverly Lorell, Douglas B. Sawyer
  • Methods for treating muscle diseases and disorders
    Patent number: 8026213
    Abstract: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: September 27, 2011
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Robert Sklar, Mark Marchionni, David I. Gwynne
  • Glial mitogenic factors, their preparation and use
    Patent number: 7968678
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Grant
    Filed: December 27, 2007
    Date of Patent: June 28, 2011
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles
  • METHODS FOR TREATING MUSCLE DISEASES AND DISORDERS
    Publication number: 20110144015
    Abstract: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.
    Type: Application
    Filed: May 17, 2010
    Publication date: June 16, 2011
    Inventors: Robert Sklar, Mark Marchionni, David I Gwynne
  • Methods for treating congestive heart failure
    Publication number: 20100267618
    Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.
    Type: Application
    Filed: December 29, 2009
    Publication date: October 21, 2010
    Inventors: Mark Marchionni, Ralph Kelly, Beverly Lorell, Douglas B. Sawyer
  • Methods for treating muscle diseases and disorders
    Patent number: 7718606
    Abstract: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.
    Type: Grant
    Filed: June 10, 2008
    Date of Patent: May 18, 2010
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Robert Sklar, Mark Marchionni, David I. Gwynne
  • Methods for treating congestive heart failure
    Patent number: 7662772
    Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.
    Type: Grant
    Filed: August 22, 2003
    Date of Patent: February 16, 2010
    Assignees: Acorda Therapeutics, Inc., Beth Israel Deaconess Medical Center, The Brigham and Women's Hospital, Inc.
    Inventors: Mark Marchionni, Ralph Kelly, Beverly Lorell, Douglas B. Sawyer
  • Glial mitogenic factors, their preparation and use
    Publication number: 20090246867
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Application
    Filed: December 27, 2007
    Publication date: October 1, 2009
    Inventors: Andrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles
  • Methods for treating muscle diseases and disorders
    Publication number: 20090018073
    Abstract: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.
    Type: Application
    Filed: June 10, 2008
    Publication date: January 15, 2009
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Robert Sklar, Mark Marchionni, David I. Gwynne